Member Info for RollingInIt

Quote _____ The CEO in the pod-cast stated at 8.54 mins in that 'NXP002 could be transformational in the field of fibrosis' then went on to say 'expecting to announce interesting data early in the new year (ref. NXP002)' _____ That's the antipodes of the previous quote. _____ didn't hear the bit where it was mentioned the news in early 2018 RE NPX002 would be transformational - may have missed it mind you ... could you give the time in the pod cast where 'transformational' was used ... cheers .. _____ Funny that. Try sticking to the facts in future rather than the act one, scene one, benign denials. As for the 'granite city geezer' quote. Thought you only played the ball and not the man. More pretence at sincerity. Yawn.

#NFX No doubt about it, best value early stage Pharma out there, albeit it is main market not AIM. Expectation is an exit via trade sale at north of 100p within 2 years, hence all major shareholders have voluntarily locked themselves in. #multibagger #money #investing twitter.com/Michelle77711/… #NFX Next WAVE of buyers will be snapping them up from the off tomorrow. Due to VERY SMALL FREE FLOAT this moves fast and more and more shares are headed to sticky investors, pushing price up even more. Would not be surprised to see broker target smashed this week #MULTIBAGGER twitter.com/Michelle77711/… #NFX Have a read of the prospectus.. FACT, major shareholders are voluntarily locked in (concert party) FACT around 20% of issued shares is in free float FACT As more shares are held by PI's for longer term the free float diminishes FACT we are just at IPO price twitter.com/kingburg81/sta… #NFX FACT They have just done a licensing deal for £2.5m plus double digit royalties for the Chinese market, a multi £B market for this drug alone FACT They have patents to protect the IP in all major regions globally FACT the American market will be much more lucrative twitter.com/kingburg81/sta… #NFX FACT the next drug for Fibrosis is much much more lucrative FACT the NFX drug versions are more effective that the current 'branded' versions FACT NFX drugs will be first to market generics twitter.com/kingburg81/sta… 1:00 PM - 17 Dec 2017 #NFX FACT first to market generics have a guaranteed market as state health providers automatically buy generic versions FACT They have a pipeling of other drugs in development FACT comparative companies/deals done at where NFX will be within 2 years are around £400m to £1B #NFX FACT NFX are fully funded for the work the need to do, and have furtherrevenues to come in FACT no need for further dilution FACT the drugs being developed by NFX do not need clinical trials as they are considered polymorphs of existing drugs by FDA and other regulators #NFX No worries Kingburg81, personally I see no need to ramp this as the facts speak for themselves, although I will no doubt be accused of ramping, The facts on this are fantastic, could be a unicorn within a couple of years 1:20 PM - 17 Dec 2017

Chalmer A little differentiation between reasoned logic and pure and simple paranoia wouldn't go amiss. Your Quote: _____ I just wonder how Inner Harmony is doing with his £100 bet on the back of the ABM ramp back in October? _____ Another Quote: _____ Same old names come out of the woodwork... On time...? _____ For someone who joined at the end of November, that's a little unusual. Hence the Multi ID logical conclusion. Here's another Quote: _____ Someone with only 24 posts and so au fait with how LSE admin works getting troublesome posters removed? _____ Now that's pure paranoia but funny also that because I'd written only 24 posts, you felt that it was odd that I was up to speed about processes on here, despite me having been a member since August 2015. Funnier still then on that basis, that you, having only been a member for less than a month, are 'au fait with how LSE Admin works' Reasoned logic with evidence. You're a fraud Chalmer.

Talking of 'recent history', Chalmer, your profile was created less than a month ago. A prime candidate for a Multi ID user.

As predicted, the paranoia returns. A few simple facts. I'm not Scottish, I don't live in Scotland and I'm not ashamed to say that I've never visited Aberdeen. Call me oldfashioned but at a guess, Aberdeenman uses that name for a geographical reason. Further, both you and Aberdeenman use 'Xmas', or remove the Christ from Christmas. I find that irritating, which isn't the point but it's not something I'd do or would want to do for exactly that reason. Time to choose another poster to direct your inaccurate accusations at.

Not true at all Inner H. Quote: ''some people have a problem with facts' You're not 'playing the ball' with that statement, you're 'playing the man (men)' Suggest you practice what you preach. Most disingenuous. Birds of a feather. Unconvinced by your repeated claim to be playing it straight. £100 indeed.

Quote: 'some people have a problem with facts' Quite right, particularly your chum, Chalmer, who's paranoia drove him to accuse me of being Aberdeenman, incorrectly, amongst other false paranoid accusations and who purports to deride 'speculation'. Speculation is made on all investments. Amazed that fact hadn't been spotted. Odd choice of bedfellow, IH. Questionable.

.. after posting this but I care not. Any researched information about a stock I'm invested in is of interest. Aberdeenman has his own website/blog referred to in his Tweets today and the following was posted on it today too: ______ As I predicted on here about 3 weeks ago, fantastic news arrived for Nuformix. The company is now generating revenue and has no need to raise additional funds (dilution/debt etc.) Those that got in early this week, as I tweeted, would already have more than bagged. HOWEVER we are only just back at IPO price and social media is absolutely buzzing about the prospects here, Remember the P/E multiple for pharma of >>24 and extrapolate where this company is going. It has been set up to be taken out within 2 years or so, for somewhere in the region of £400m to £1B, so north of 100p per share. Shorter term the broker, whilst VERY conservative price wise, reckons 10p is fair. I think we shall see 8p-10p this week easily. That is another bag in time for Xmas. I got a power of abuse from trolls about this one, yet again I have proven them wrong, this is a giant in the making. They should hang their heads in shame for trying to deny people the opportunity to make some serious money. Watch out for further licensing deals, especially the American one(s) that will rocket this up to above 20p per share. Other stuff to come from me but I will save that for later. Important message is those in earliest get the biggest gains, and we are still at IPO price, so perfect time to load up.

TECH can acquire 90% of Cedex if they take up the $40k option, which can be offset against the loan they've made. No brainer if it's a rip roaring success as predicted. In the RNS. 'Under the Heads of Terms, TechFinancials will make unsecured loan funding of US$400,000 available to the CEDEX group to develop its technology. The loan bears no interest. TechFinancials can seek repayment of the loan once CEDEX has sufficient funds and the loan therefore has no set maturity date. #### In consideration for providing this initial funding, upon incorporation of the CEDEX holding company ("CEDEX HoldCo"), CEDEX HoldCo will grant the Company an option to acquire 90 per cent of CEDEX HoldCo at an exercise price of US$40,000, which may be offset against any amount outstanding under the loan. #### Exercise of the option is at the sole discretion of TechFinancials and the option can be transferred, sold or disposed of as TechFinancials sees fit. The option period is for three years from the date of grant.

Take a look at his Tweets about NFX (just put 'Aberdeenman Twitter' in Google if you're not on Twitter). This isn't to suggest that relying on something written by someone you don't know is a valid reason to risk capital but I found his forecasts of interest. There's a Biblical reference (at least I think it is !), which is 'judge a prophet by his works', roughly meaning ' were the prophecies accurate ?' As always, do your own research and the caveat should always remain that past performance is not a guarantee of future performance. However, if you look at Aberdeenman's predictions (before events unfolded) in his Tweets about NFX, he's been bang on so far. Furthermore, if you look at what he's predicting going forward for NFX, it makes for even more interesting reading.

You appear long enough in the tooth, without wishing to offend, to know the games that brokers, investors, frankly all market participants, play en route to revaluations higher or lower, so any flighty manouvres by a broker along the way should be of no surprise. I don't wish to see anyone on the wrong end of a trading position and can't offer protection against it, including for myself, but often the attempts at over analysis miss the sentiment associated with a stocks price developments. A share price often reflects the sentiment of what will be or the belief of what will be prior to events and as much as giving caution is a good thing, excessive caution can result in missing the opportunity. Each to their own and I wish you well with whatever direction your choices take you.

Nuformix (NFX.L), the Cambridge-based pharmaceutical development company which specialises in cocrystal technology to unlock new and improved therapeutic uses for already known and safe drugs, has announced a key out-licensing deal with Shanghai Newsummit Biopharma Group. Under the deal agreement, NFX will receive upfront payments of some £2.5m in addition to a double digit royalty stream on all Newsummit revenues derived from the NXP001 product in the Chinese market. Importantly, this deal rubber stamps NFX’s cocrystal technology, it provides fresh income to help finance product development and should provide a strong and rising royalty income stream going forward. Cocrystal Technology Solves Several Drug Development Problems The clever part of NFX’s drug development programme is that of utilising cocrystal technology as a new approach to overcome current performance limitations of safe, known drugs. Known safety equates to lower development costs, shorter timescales and overall reduced risks, thus NFX’s risk/reward profile compares very favourably to its peers. Billion Dollar Treatment Fields NFX has two main drug development programmes; one in the cUS$ 20bn treatment field of Oncology Supportive Care (OSC) and the other in the potentially even larger emerging Fibrosis treatment area. New drugs in both areas are highly sought after by big pharma, as today’s deal highlights. Valuation and Recommendation Nuformix is currently fully funded for its two key development programmes NXP001 and NXP002 for the coming 18 months, but today’s announcement on the NXP001 programme, rubber stamps NFX’s cocrystal technology, whilst providing fresh near-term funding and longer term, a royalty stream. This is clearly very positive for NFX and prompts us to raise our target price significantly, to 10p per share (from 5p) and we reiterate our Speculative Buy recommendation. _____ Nothing hubristic in there Inner-Harmony, and plenty of fundamental rationale.

They'll be providing security for Blockchain with Thales. Blockchain is the rage.

I think securing Blockchain with a patented platform is far more appealling than your beloved AST that you keep buying as it's dropping in price. Your statement sounds very much like you're a fully paid up member of Share Prophets and worried about your short positiion. Never mind.

Poached from Advfn today. aimshare10 Dec '17 - 09:19 - 80271 of 80305    12   0 Warren Blockchain needs security at scale to secure the implementation of digital wallets, which have not been well protected. Organisations using Blockchain will need a Hardware Security Module (HSM). Thales nShield HSM to secure Blockchain will be using Tern's Device Authority Keyscaler Platform to deliver the highest level of security. So, the short version is that Tern (Device Authority) will be involved in securing Blockchain. Huge news, given the explosion in Blockchain ! :o)